 and functional deterioration in improved survival rates in patients with ALS treated with Neurosensis Prime C, which is a fixed-dose combo of two FDA-approved drugs. NVIDIA's dominance is providing chips to power AI tech is attracting the attention of regulators. According to Reuters, France's antitrust regulator is about to charge NVIDIA with alleged anti-competitive practices. That's your money now.